Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4365MR)

This product GTTS-WQ4365MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4365MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15054MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ2100MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ115MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ12407MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ2216MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ3119MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ10636MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ7961MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GX-17
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW